Overview

FMISO-PET in Brain Tumors and SCS Effect

Status:
Terminated
Trial end date:
2017-09-17
Target enrollment:
Participant gender:
Summary
The aim of this study is to assess, with 18F-FMISO PET, hypoxia in high grade gliomas and changes by spinal cord stimulation in a subset of patients. Additionally, the potential correlation with pathological, imaging and clinical parameters will be analyzed.
Phase:
Phase 2
Details
Lead Sponsor:
Bernardino Clavo, MD, PhD
Collaborators:
Fundación DISA, Canary Islands, Spain
Grupo de Investigación Clínica en Oncología Radioterapia
Instituto Canario de Investigación del Cáncer
Instituto de Salud Carlos III
Instituto Tecnologico Servicios Sanitarios, in MD Anderson Cancer Center, Madrid
RSbiomed
Treatments:
Dacarbazine
Misonidazole
Temozolomide